HomeNewsIndiaGlobal supply of COVAX hit due to coronavirus crisis in India, USAID tells lawmakers

Global supply of COVAX hit due to coronavirus crisis in India, USAID tells lawmakers

"COVAX has suffered a big blow given the scale of the pandemic in India," Samantha Power, Administrator of the US Agency for International Development (USAID), told members of the Senate Appropriations Subcommittee on State and Foreign Operations for a hearing on the Fiscal 2022 Budget Request for the USAID.

May 28, 2021 / 08:29 IST
Story continues below Advertisement
The WHO has said that "more information" is "required" from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19.
The WHO has said that "more information" is "required" from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19.

Due to the unprecedented COVID-19 crisis in India, the global supply of COVAX has been badly hit, so much so that there are many parts of the world where one shot has been dispensed to health workers or frontline workers and the second shot has not been forthcoming, a top Biden administration official told lawmakers on Thursday.

"COVAX has suffered a big blow given the scale of the pandemic in India," Samantha Power, Administrator of the US Agency for International Development (USAID), told members of the Senate Appropriations Subcommittee on State and Foreign Operations for a hearing on the Fiscal 2022 Budget Request for the USAID.

Story continues below Advertisement

"The Serum Institute of India, which had planned to supply upwards of 140 million doses by the end of June, has had to pull back that supply because of the domestic emergency," Power said responding to a question on the vaccine crisis that has been created across the globe due to the scale of the pandemic in India.

"COVAX now is looking to countries like ours and other countries around the world to contribute supply, to donate supply," she said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show